The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce 63 students from 41 academic institutions have been selected to take part in the 2024 NIIMBL eXperience, the largest cohort since the Program’s launch in 2019. Students will participate in one of five NIIMBL eXperience programs hosted by Albany...

This April marks three years since BioMADE officially launched. The successes our industry has seen over the last three years would not be possible without our incredible 275+ member organizations and our partners in the U.S. government. The past year has held many milestones for BioMADE, including announcing nine new projects to advance domestic...

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) officially launches the Viral Vectors NIIMBL-led Program focused on developing and making broadly available robust, economically viable, shared manufacturing process and analytical platforms for Adeno-Associated Virus (AAV) gene therapy vectors. NIIMBL has committed...

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce approximately $1.7M in planned project activities through the Institute’s Global Health Fund (GHF) Project Call 6.1G for three new projects focused on the development of in vitro potency assays for vaccines being produced by mRNA and/or viral...

The NIIMBL eXperience is an exclusive in-person, all expenses paid immersion program that offers you real-world insight into biopharmaceutical industry careers through hands-on activities and direct interactions with industry professionals. The program targets African American/Black, Latinx, and Native...